Phosphorylation of Mcardle Phosphorylase Induces Activity (Human Skeletal Muscle/Protein Kinase) CESARE G

Total Page:16

File Type:pdf, Size:1020Kb

Phosphorylation of Mcardle Phosphorylase Induces Activity (Human Skeletal Muscle/Protein Kinase) CESARE G Proc. Nati. Acad. Sci. USA Vol. 78, No. 5, pp. 2688-2692, May 1981 Biochemistry Phosphorylation of McArdle phosphorylase induces activity (human skeletal muscle/protein kinase) CESARE G. CERRI AND JOSEPH H. WILLNER Department of Neurology and H. Houston Merritt Clinical Research Center for Muscular Dystrophy and Related Diseases, Columbia University College of Physicians and Surgeons, New York, New York 10032 Communicated by Harry Grundfest, January 7, 1981 ABSTRACT In McArdle disease, myophosphorylase defi- mediate between those of phosphorylases b and a. Karpatkin ciency, enzyme activity is absent but the presence of an altered et al. (19, 20) found that incubation of human platelets with enzyme protein can frequently be demonstrated. We have found MgATP+ resulted in an increase in total phosphorylase activity that phosphorylation of this protein in vitro can result in catalytic and concluded that the data were "consistent with the presence activity. We studied muscle of four patients; all lacked myophos- in human platelets of inactive dimer and monomer species of phorylase activity, but myophosphorylase protein was demon- phosphorylase, which require MgATP for activation." Because strated by immunodiffusion or gel electrophoresis. Incubation of activation of these isozymes was probably due to protein phos- muscle homogenate supernatants with cyclic AMP-dependent pro- phorylation and also because incomplete phosphorylation could tein kinase and ATP resulted in phosphorylase activity. The ac- tivated enzyme comigrated with normal human myophosphory- result in reduced activity, we evaluated the possibility that the lase in gel electrophoresis. Incubation with [y-32P]ATP resulted activity ofphosphorylase in McArdle muscle could be restored in incorporation of 32P into the band possessing phosphorylase by phosphorylation of the inactive phosphorylase protein pres- activity. Activation of phosphorylase by cyclic AMP-dependent ent in some patients. protein kinase was inhibited by antibodies to normal human my- ophosphorylase or by inhibitory protein to cyclic AMP-dependent MATERIALS AND METHODS protein kinase. Incubation of muscle homogenates with phos- EDTA, peak II ofcAMP-Kase from bovine heart, phosphorylase phorylase b kinase and ATP also resulted in phosphorylase activ- b kinase, protein kinase inhibitor (from rabbit skeletal muscle), ity. After the action of cyclic AMP-dependent protein kinase, the glycogen, 2-mercaptoethanol, Na ,B-glycerophosphate, di- resulting activity was similar to that ofphosphorylase b. However, thiothreitol, ATP, theophylline, cAMP, AMP, cysteine, NADP, incubation with phosphorylase kinase resulted in activity similar phosphoglucomutase, glucose-6-phosphate dehydrogenase, and to that ofphosphorylase a. For several reasons, it is not likely that Coomassie brilliant blue were purchased from Sigma. By gel McArdle disease is due to lack ofnormal phosphorylation, but res- electrophoresis, there was no evidence that the cAMP-Kase was toration of activity to the mutant protein by phosphorylation may contaminated by phosphorylase b kinase or that the preparation provide a clue to understanding the mechanism of this genetic of phosphorylase b kinase contained cAMP-Kase; only a single defect. dense band migrated in electrophoresis of either preparation. With histone as substrate, we found no cAMP-Kase activity in McArdle disease is due to genetic lack ofphosphorylase (1,4-a- the phosphorylase b kinase, as determined by the method of D-glucan:orthophosphate a-D glucosyltransferase, EC 2.4.1.1) Keely (21); conversely, the cAMP-Kase preparation was unable activity in skeletal muscle (1). In some patients, the enzyme to activate phosphorylase b, as determined by the method of protein seems to be absent (2). In others, the presence ofphos- Krebs (22). [y-32P]ATP, Aquassure, and Protosol were obtained phorylase can be demonstrated immunologically (3, 4) or by gel from New England Nuclear. Acrylamide and (N,N'-methyl- electrophoresis (2), but the protein lacks catalytic activity. ene)bisacrylamide were purchased from BioRad. All other re- In normal mammalian skeletal muscle, phosphorylase is agents were ofthe highest purity available and were purchased present in at least two differently active states, phosphorylase from Fisher. Antibodies to normal human skeletal muscle phos- a and phosphorylase b (5-7). Phosphorylase b consists of two phorylase, a gift of S. DiMauro, were characterized previously monomers (8) and requires AMP for full expression of activity (23). (9-11). Phosphorylase a, a dimer ofidentical subunits, can also The diagnosis of McArdle disease in the four patients we be activated by AMP at high temperatures and low substrate studied was established by biochemical, histochemical, and concentrations (12) but is usually considered to be active in the clinical criteria (24). Muscle biopsies were performed with in- absence of AMP (7). The conversion from phosphorylase b to formed consent under local anesthesia; specimens for biochem- phosphorylase a depends on phosphorylation of a serine in po- ical study were frozen and stored in liquid nitrogen until sition 14 ofthe amino acid backbone ofthe phosphorylase mono- analyzed. mer and is catalyzed by phosphorylase b kinase, which in turn In all the McArdle muscles we studied, phosphorylase pro- is activated by either Ca + or 3',5'-cyclic AMP (cAMP)-depen- tein was demonstrated by gel electrophoresis. In each of two dent protein kinase (cAMP-Kase) (13, 14). Protein phosphatases muscles also analyzed in Ouchterlony plates, we found cross- dephosphorylate and inactivate phosphorylase a (15), convert- reacting material to antibody against human myophosphorylase. ing it back to phosphorylase b. We did not have access to a patient in whom phosphorylase Gergely and Bot described partially phosphorylated hybrid protein was not identified by these techniques. forms of phosphorylase in rabbit muscle (16, 17) and human Fragments of muscle were pulverized in a mortar cooled to platelets (18). The activities of these isoenzymes were inter- liquid nitrogen temperature. To the powder, we added 6 vol of 60% glycerol (voVvol)/20 mM 2-mercaptoethanol/10 mM The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertise- Abbreviations: cAMP, 3',5'-cyclic AMP; cAMP-Kase, cAMP-depen- ment" in accordance with 18 U. S. C. §1734 solely to indicate this fact. dent protein kinase. 2688 Downloaded by guest on September 28, 2021 Biochemistry: Cerri and Willner Proc. Natl. Acad. Sci. USA 78 (1981) 2689 EDTA/50 mM NaF/40 mM /3-glycerophosphate (pH 6.8) (glyc- dide (4%) in 7% acetic acid. Some gels were destained and erol/buffer A). The frozen suspension was then transferred with stained with Coomassie brilliant blue [1.25 g in methanoVgla- a spatula to an all-glass homogenizer, diluted 1:1 with buffer A, cial acetic acid/distilled water (227:46:227)]. and homogenized (25). In most experiments, the supernatant To correlate the amount of radioactive phosphate incorpo- obtained after centrifugation at 15,000 rpm for 10 min in a Sor- rated to the amount ofphosphorylase activity induced, ATP in vall refrigerated centrifuge was dialyzed in a membrane that the preincubation mixture was labeled with 100 mCi/mmol (1 excluded proteins larger than 12,000 daltons for 2 hr at 40C Ci = 3.7 X 1010 becquerels) of [y-32P]ATP. Aliquots of the in- against 500 vol of buffer A. Without further treatment, this su- cubation mixture were transferred to a "stop solution" (100 mM pernatant was used for assays. To remove endogenous AMP, NaF/10 mM EDTA) after 6, 10, and 15 min. Subsequently, some homogenates were treated with Norit A (20). Protein was these aliquots were assayed for phosphorylase activity and sub- determined according to Lowry (26). jected to electrophoresis. We also dephosphorylated 32P-la- To monitor phosphorylase activity by a continuous reaction, beled phosphorylase in the McArdle supernatant to by dialysis we used the method of Layzer (27), with minor modifications. against 100 mM imidazole/10 mM theophylline/20 mM 2-mer- The reaction mixture contained 2 mM MgCl2, 1 mM NADP, captoethanol (pH 7.0) at 4°C for 40 min in the absence ofprotein 1% glycogen, 5 units of phosphoglucomutase, and 3 units of phosphatase inhibitor; phosphorylase activities and amounts of glucose-6-phosphate dehydrogenase in 20 mM Na phosphate 2p incorporated were measured before and after dialysis. Gels buffer (pH 7.2). were dried and cut with a sharp razor at 2-mm intervals. Percent The effects of cAMP-Kase and phosphorylase b kinase were of gel protein radioactivity was calculated as the difference be- determined by their direct addition to the reaction mixture. To tween the radioactivity ofthe band migrating with, and staining monitor the effect of cAMP-Kase, we added 100 ,1 of dialyzed as, human phosphorylase and the parallel position in the strip supernatant, 5.0 nmol of cAMP, 0.5 ,mol of ATP, and up to incubated with reaction mixture and no muscle divided by the 200 picounits of cAMP-Kase. After 15 min at 30°C, we then total radioactivity bound to protein in the strip that contained added 0.8 ,mol of AMP to the reaction mixture. The effect of supernatant. phosphorylase b kinase was determined by adding 100 ,ul of dialyzed supernatant, 0.5 ,mol ofATP, and up to 150 picounits RESULTS ofphosphorylase b kinase. The change in absorbance at 340 nm No residual phosphorylase enzyme activity was detected in ho- was measured with a Beckman type
Recommended publications
  • Enzymatic Encoding Methods for Efficient Synthesis Of
    (19) TZZ__T (11) EP 1 957 644 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C12N 15/10 (2006.01) C12Q 1/68 (2006.01) 01.12.2010 Bulletin 2010/48 C40B 40/06 (2006.01) C40B 50/06 (2006.01) (21) Application number: 06818144.5 (86) International application number: PCT/DK2006/000685 (22) Date of filing: 01.12.2006 (87) International publication number: WO 2007/062664 (07.06.2007 Gazette 2007/23) (54) ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES ENZYMVERMITTELNDE KODIERUNGSMETHODEN FÜR EINE EFFIZIENTE SYNTHESE VON GROSSEN BIBLIOTHEKEN PROCEDES DE CODAGE ENZYMATIQUE DESTINES A LA SYNTHESE EFFICACE DE BIBLIOTHEQUES IMPORTANTES (84) Designated Contracting States: • GOLDBECH, Anne AT BE BG CH CY CZ DE DK EE ES FI FR GB GR DK-2200 Copenhagen N (DK) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI • DE LEON, Daen SK TR DK-2300 Copenhagen S (DK) Designated Extension States: • KALDOR, Ditte Kievsmose AL BA HR MK RS DK-2880 Bagsvaerd (DK) • SLØK, Frank Abilgaard (30) Priority: 01.12.2005 DK 200501704 DK-3450 Allerød (DK) 02.12.2005 US 741490 P • HUSEMOEN, Birgitte Nystrup DK-2500 Valby (DK) (43) Date of publication of application: • DOLBERG, Johannes 20.08.2008 Bulletin 2008/34 DK-1674 Copenhagen V (DK) • JENSEN, Kim Birkebæk (73) Proprietor: Nuevolution A/S DK-2610 Rødovre (DK) 2100 Copenhagen 0 (DK) • PETERSEN, Lene DK-2100 Copenhagen Ø (DK) (72) Inventors: • NØRREGAARD-MADSEN, Mads • FRANCH, Thomas DK-3460 Birkerød (DK) DK-3070 Snekkersten (DK) • GODSKESEN,
    [Show full text]
  • (Glycogen Storage Disease Type V) and Anesthesia a Case Report And
    Pediatric Anesthesia ISSN 1155-5645 REVIEW ARTICLE McArdle’s disease (glycogen storage disease type V) and anesthesia – a case report and review of the literature Georg Bollig1,2 1 Department of Anesthesiology and Intensive Care, Palliative Medicine and Pain Therapy, HELIOS Klinikum Schleswig, Schleswig, Germany 2 Department of Surgical Sciences, Haukeland University Hospital, University of Bergen, Bergen, Norway Keywords Summary general anesthesia; glycogen storage disease; glycogen storage disease type V; McArdles disease (glycogen storage disease type v) is a rare condition in malignant hyperthermia; McArdles disease; which energy-metabolism in the muscle is hampered. A case report is pre- perioperative complications sented and the possible risk for perioperative complications including malig- nant hyperthermia is discussed. A checklist for the anesthesiological Correspondence management of patients with McArdles disease is provided. A short overview Georg Bollig, Department of Anesthesiology of anesthesiological challenges and perioperative complications of other gly- and Intensive Care, Palliative Medicine and Pain Therapy, HELIOS Klinikum Schleswig, cogen storage diseases is given. Schleswig, Germany Email: [email protected] Section Editor: Barbara Brandom Accepted 3 March 2013 doi:10.1111/pan.12164 tachycardia and hypotonia occurred. After the opera- Introduction tion, the anesthesiologist informed the patient about the McArdle’s disease is a rare condition in which energy event and the fact that he had elevated liver enzymes metabolism in the muscle is hampered. A case report (aspartate transaminase = AST, alanine transaminase = will be presented, and the possible risk of perioperative ALT, and lactate dehydrogenase = LDH). An overview problems including malignant hyperthermia is dis- of the patient’s anesthesiological history is given in cussed.
    [Show full text]
  • Guaiacol As a Drug Candidate for Treating Adult Polyglucosan Body Disease
    Guaiacol as a drug candidate for treating adult polyglucosan body disease Or Kakhlon, … , Wyatt W. Yue, H. Orhan Akman JCI Insight. 2018;3(17):e99694. https://doi.org/10.1172/jci.insight.99694. Research Article Metabolism Therapeutics Graphical abstract Find the latest version: https://jci.me/99694/pdf RESEARCH ARTICLE Guaiacol as a drug candidate for treating adult polyglucosan body disease Or Kakhlon,1 Igor Ferreira,2 Leonardo J. Solmesky,3 Netaly Khazanov,4 Alexander Lossos,1 Rafael Alvarez,5 Deniz Yetil,6 Sergey Pampou,7 Miguel Weil,3,8 Hanoch Senderowitz,4 Pablo Escriba,5 Wyatt W. Yue,2 and H. Orhan Akman9 1Department of Neurology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. 2Structural Genomics Consortium, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.3 Cell Screening Facility for Personalized Medicine, Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel. 4Department of Chemistry, Bar Ilan University, Ramat Gan, Israel. 5Laboratory of Molecular Cell Biomedicine, Department of Biology, University of the Balearic Islands, Palma de Mallorca, Spain. 6Connecticut College, Newington, Connecticut USA. 7Columbia University Department of Systems Biology Irving Cancer Research Center, New York, New York, USA. 8Laboratory for Neurodegenerative Diseases and Personalized Medicine, Department of Cell Research and Immunology, The George S. Wise Faculty for Life Sciences, Sagol School of Neurosciences, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel. 9Columbia University Medical Center Department of Neurology, Houston Merritt Neuromuscular diseases research center, New York, New York, USA. Adult polyglucosan body disease (APBD) is a late-onset disease caused by intracellular accumulation of polyglucosan bodies, formed due to glycogen-branching enzyme (GBE) deficiency.
    [Show full text]
  • A Genome Based Discovery of S. Mansoni Secretome to Identify Therapeutic Targets
    ics om & B te i ro o P in f f o o Mandage et al. J Proteomics Bioinform 2011, 4:3 r l m a Journal of a n t r i c u DOI: 10.4172/jpb.1000168 s o J ISSN: 0974-276X Proteomics & Bioinformatics Research Article Article OpenOpen Access Access A Genome Based Discovery of S. mansoni Secretome to Identify Therapeutic Targets Mandage RH1*, Jadhavrao PK2, Wadnerkar AS1, Varsale AR1 and Kurwade KK1 1Dept of Bioinformatics, Centre for Advanced Life Sciences, Deogiri College, Aurangabad 431005, M.S. India 2Dept of Microbiology, Abeda Inamdar College, Pune 411001, M.S. India Abstract The motivation behind the large scale genome analysis of S. mansoni was to explore the possibility of discovering the secretome that is frequently secreted at the interface of parasite and host is supposed to play a crucial role in parasitism by suppressing the immune response, to aid the proliferation of infectivity. Here, we present an efficient pipeline of bioinformatics methodology to identify candidate parasitism proteins within S. mansoni secretome of immune responses in the infected host. The 3,700 proteins deduced from the S. mansoni genome were analysed for the presence or absence of secretory signal peptides. We identified 32 proteins carrying an N-terminal secreted signal peptide but deficient in extra membrane-anchoring moieties. Notably we identified proteins involved in ATP synthesis, redox balance, protein folding, gluconeogenesis, development and signaling, scavenging and nucleotide metabolic pathways, immune response modulation. Most of these proteins define their potential for immunological diagnosis and vaccine design. A systematic attempt has been made here to develop a general method for predicting secretory proteins of a parasite with high efficiency and accuracy.
    [Show full text]
  • An Evolving Hierarchical Family Classification for Glycosyltransferases
    doi:10.1016/S0022-2836(03)00307-3 J. Mol. Biol. (2003) 328, 307–317 COMMUNICATION An Evolving Hierarchical Family Classification for Glycosyltransferases Pedro M. Coutinho1, Emeline Deleury1, Gideon J. Davies2 and Bernard Henrissat1* 1Architecture et Fonction des Glycosyltransferases are a ubiquitous group of enzymes that catalyse the Macromole´cules Biologiques transfer of a sugar moiety from an activated sugar donor onto saccharide UMR6098, CNRS and or non-saccharide acceptors. Although many glycosyltransferases catalyse Universite´s d’Aix-Marseille I chemically similar reactions, presumably through transition states with and II, 31 Chemin Joseph substantial oxocarbenium ion character, they display remarkable diversity Aiguier, 13402 Marseille in their donor, acceptor and product specificity and thereby generate a Cedex 20, France potentially infinite number of glycoconjugates, oligo- and polysacchar- ides. We have performed a comprehensive survey of glycosyltransferase- 2Structural Biology Laboratory related sequences (over 7200 to date) and present here a classification of Department of Chemistry, The these enzymes akin to that proposed previously for glycoside hydrolases, University of York, Heslington into a hierarchical system of families, clans, and folds. This evolving York YO10 5YW, UK classification rationalises structural and mechanistic investigation, harnesses information from a wide variety of related enzymes to inform cell biology and overcomes recurrent problems in the functional prediction of glycosyltransferase-related open-reading frames. q 2003 Elsevier Science Ltd. All rights reserved Keywords: glycosyltransferases; protein families; classification; modular *Corresponding author structure; genomic annotations The biosynthesis of complex carbohydrates and are involved in glycosyl transfer and thus conquer polysaccharides is of remarkable biological import- what Sharon has provocatively described as “the ance.
    [Show full text]
  • Generate Metabolic Map Poster
    Authors: Pallavi Subhraveti Ron Caspi Peter Midford Peter D Karp An online version of this diagram is available at BioCyc.org. Biosynthetic pathways are positioned in the left of the cytoplasm, degradative pathways on the right, and reactions not assigned to any pathway are in the far right of the cytoplasm. Transporters and membrane proteins are shown on the membrane. Ingrid Keseler Periplasmic (where appropriate) and extracellular reactions and proteins may also be shown. Pathways are colored according to their cellular function. Gcf_000702945Cyc: Clostridium sp. KNHs205 Cellular Overview Connections between pathways are omitted for legibility.
    [Show full text]
  • Chem331 Glycogen Metabolism
    Glycogen metabolism Glycogen review - 1,4 and 1,6 α-glycosidic links ~ every 10 sugars are branched - open helix with many non-reducing ends. Effective storage of glucose Glucose storage Liver glycogen 4.0% 72 g Muscle glycogen 0.7% 245 g Blood Glucose 0.1% 10 g Large amount of water associated with glycogen - 0.5% of total weight Glycogen stored in granules in cytosol w/proteins for synthesis, degradation and control There are very different means of control of glycogen metabolism between liver and muscle Glycogen biosynthetic and degradative cycle Two different pathways - which do not share enzymes like glycolysis and gluconeogenesis glucose -> glycogen glycogenesis - biosynthetic glycogen -> glucose 1-P glycogenolysis - breakdown Evidence for two paths - Patients lacking phosphorylase can still synthesize glycogen - hormonal regulation of both directions Glycogenolysis (glycogen breakdown)- Glycogen Phosphorylase glycogen (n) + Pi -> glucose 1-p + glycogen (n-1) • Enzyme binds and cleaves glycogen into monomers at the end of the polymer (reducing ends of glycogen) • Dimmer interacting at the N-terminus. • rate limiting - controlled step in glycogen breakdown • glycogen phosphorylase - cleavage of 1,4 α glycosidic bond by Pi NOT H2O • Energy of phosphorolysis vs. hydrolysis -low standard state free energy change -transfer potential -driven by Pi concentration -Hydrolysis would require additional step s/ cost of ATP - Think of the difference between adding a phosphate group with hydrolysis • phosphorylation locks glucose in cell (imp. for muscle) • Phosphorylase binds glycogen at storage site and the catalytic site is 4 to 5 glucose residues away from the catalytic site. • Phosphorylase removes 1 residue at a time from glycogen until 4 glucose residues away on either side of 1,6 branch point – stericaly hindered by glycogen storage site • Cleaves without releasing at storage site • general acid/base catalysts • Inorganic phosphate attacks the terminal glucose residue passing through an oxonium ion intermediate.
    [Show full text]
  • Endoplasmic Reticulum Stress Induces Myostatin High Molecular Weight Aggregates and Impairs Mature Myostatin Secretion
    Molecular Neurobiology https://doi.org/10.1007/s12035-018-0997-9 Endoplasmic Reticulum Stress Induces Myostatin High Molecular Weight Aggregates and Impairs Mature Myostatin Secretion Rishibha Sachdev1,2 & Karin Kappes-Horn3 & Lydia Paulsen1 & Yvonne Duernberger1 & Catharina Pleschka1 & Philip Denner1 & Bishwajit Kundu2 & Jens Reimann3 & Ina Vorberg1,4 Received: 30 August 2017 /Accepted: 7 March 2018 # The Author(s) 2018 Abstract Sporadic inclusion body myositis (sIBM) is the most prevalent acquired muscle disorder in the elderly with no defined etiology or effective therapy. Endoplasmic reticulum stress and deposition of myostatin, a secreted negative regulator of muscle growth, have been implicated in disease pathology. The myostatin signaling pathway has emerged as a major target for symptomatic treatment of muscle atrophy. Here, we systematically analyzed the maturation and secretion of myostatin precursor MstnPP and its metabolites in a human muscle cell line. We find that increased MsntPP protein levels induce ER stress. MstnPP metabolites were predominantly retained within the endoplasmic reticulum (ER), also evident in sIBM histology. MstnPP cleavage products formed insoluble high molecular weight aggregates, a process that was aggravated by experimental ER stress. Importantly, ER stress also impaired secretion of mature myostatin. Reduced secretion and aggregation of MstnPP metabolites were not simply caused by overexpression, as both events were also observed in wildtype cells under ER stress. It is tempting to speculate that reduced circulating myostatin growth factor could be one explanation for the poor clinical efficacy of drugs targeting the myostatin pathway in sIBM. Keywords Sporadic inclusion body myositis . ER stress . Myostatin . Amyloid precursor protein . Protein misfolding . Atrophy Introduction [5]. Pathological characteristics include vacuolated mus- cle fibers, deposition of proteinaceous material [6, 7], Sporadic inclusion body myositis (sIBM) is the most and T lymphocyte infiltration [8].
    [Show full text]
  • SEARCH Supplementary Appendix for SLCO1B1 Variants and Statin
    Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: The SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy — a genomewide study. N Engl J Med 2008;359. DOI: 10.1056/NEJMoa0801936. Supplementary Appendix for: “SLCO1B1 Variants and Statin-Induced Myopathy – A Genomewide Study” CONTENTS SEARCH Collaborative Group Supplementary Tables Supplementary Table 1: Baseline characteristics of 85 myopathy cases and 90 matched controls in SEARCH Supplementary Table 2a: Associations with myopathy for SNPs within SLCO1B1 (+/- 10kb) from the genome-wide association study, candidate genotyping and imputation in SEARCH Supplementary Table 2b: Associations with myopathy for SNPs within CYP3A4 (+/- 10kb) with myopathy in SEARCH Supplementary Table 3: LDL-cholesterol concentrations and reductions with 40mg simvastatin daily in HPS, subdivided by rs4149056 and rs2306283 SLCO1B1 genotypes Supplementary Table 4: Previous candidate gene studies of statin-induced myopathy, myalgia or intolerance (also included in Supplementary Table 5); and findings for associations of these genes with myopathy in SEARCH Supplementary Table 5: Genes previously reported to be associated with statin-induced myopathy, statin intolerance or statin pharmacokinetics; and associations with SNPs in these genes (+/- 10kb) with myopathy in SEARCH Supplementary Table 6: In vivo studies of the association between statin elimination and SLCO1B1 rs4149056 SNP Supplementary Figure Supplementary
    [Show full text]
  • Comparative Transcriptomics Reveals Lineage Specific Evolution of Cold
    bioRxiv preprint doi: https://doi.org/10.1101/151431; this version posted June 19, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Evolution of cold response in Pooideae 1 Comparative transcriptomics reveals lineage specific evolution of 2 cold response in Pooideae 3 Lars Grønvold1*, Marian Schubert2*, Simen R. Sandve3, Siri Fjellheim2 and Torgeir R. 4 Hvidsten1,4 5 *Contributed equally 6 1Department of Chemistry, Biotechnology and Food Science, Norwegian University of Life 7 Sciences, NO-1432, Ås, Norway. 8 2Department of Plant Sciences, Norwegian University of Life Sciences, Ås NO-1432, Norway. 9 3Centre for Integrative Genetics (CIGENE), Department of Animal and Aquacultural Sciences, 10 Norwegian University of Life Sciences, NO-1432, Ås, Norway. 11 4Umeå Plant Science Centre, Department of Plant Physiology, Umeå University, SE-90187, 12 Umeå, Sweden. 13 Author for correspondence: 14 Torgeir R. Hvidsten 15 Tel: +4767232491 16 Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/151431; this version posted June 19, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Evolution of cold response in Pooideae 17 Abstract 18 Background: Understanding how complex traits evolve through adaptive changes in gene 19 regulation remains a major challenge in evolutionary biology.
    [Show full text]
  • Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease
    cells Review Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease Marta Migocka-Patrzałek * and Magdalena Elias Department of Animal Developmental Biology, Faculty of Biological Sciences, University of Wroclaw, 50-335 Wroclaw, Poland; [email protected] * Correspondence: [email protected] Abstract: Glycogen phosphorylase (PG) is a key enzyme taking part in the first step of glycogenolysis. Muscle glycogen phosphorylase (PYGM) differs from other PG isoforms in expression pattern and biochemical properties. The main role of PYGM is providing sufficient energy for muscle contraction. However, it is expressed in tissues other than muscle, such as the brain, lymphoid tissues, and blood. PYGM is important not only in glycogen metabolism, but also in such diverse processes as the insulin and glucagon signaling pathway, insulin resistance, necroptosis, immune response, and phototransduction. PYGM is implicated in several pathological states, such as muscle glycogen phosphorylase deficiency (McArdle disease), schizophrenia, and cancer. Here we attempt to analyze the available data regarding the protein partners of PYGM to shed light on its possible interactions and functions. We also underline the potential for zebrafish to become a convenient and applicable model to study PYGM functions, especially because of its unique features that can complement data obtained from other approaches. Keywords: PYGM; muscle glycogen phosphorylase; functional protein partners; glycogenolysis; McArdle disease; cancer; schizophrenia Citation: Migocka-Patrzałek, M.; Elias, M. Muscle Glycogen Phosphorylase and Its Functional Partners in Health and Disease. Cells 1. Introduction 2021, 10, 883. https://doi.org/ The main energy substrate in animal tissues is glucose, which is stored in the liver and 10.3390/cells10040883 muscles in the form of glycogen, a polymer consisting of glucose molecules.
    [Show full text]
  • Molecular Pathogenesis of a New Glycogenosis Caused by a Glycogenin-1 Mutation
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1822 (2012) 493–499 Contents lists available at SciVerse ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbadis Molecular pathogenesis of a new glycogenosis caused by a glycogenin-1 mutation Johanna Nilsson a,⁎, Adnan Halim b, Ali-Reza Moslemi a, Anders Pedersen c, Jonas Nilsson b, Göran Larson b, Anders Oldfors a a Department of Pathology, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden b Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden c Swedish NMR Centre, Gothenburg, Sweden article info abstract Article history: Glycogenin-1 initiates the glycogen synthesis in skeletal muscle by the autocatalytic formation of a short ol- Received 27 June 2011 igosaccharide at tyrosine 195. Glycogenin-1 catalyzes both the glucose-O-tyrosine linkage and the α1,4 glu- Received in revised form 7 November 2011 cosidic bonds linking the glucose molecules in the oligosaccharide. We recently described a patient with Accepted 28 November 2011 glycogen depletion in skeletal muscle as a result of a non-functional glycogenin-1. The patient carried a Available online 9 December 2011 Thr83Met substitution in glycogenin-1. In this study we have investigated the importance of threonine 83 Keywords: for the catalytic activity of glycogenin-1. Non-glucosylated glycogenin-1 constructs, with various amino Glycogen acid substitutions in position 83 and 195, were expressed in a cell-free expression system and autoglucosy- Glycogenin lated in vitro.
    [Show full text]